44 articles
Jiangsu Hengrui Pharmaceuticals has licensed global rights to its weight-management drug HRS-1596 to Novo Nordisk in a deal worth up to $2.6 billion, including a $300 million upfront fee.
Novo Nordisk is exploring a direct listing on the New York Stock Exchange to replace current American depositary receipts and boost its US profile. CEO Mike Doustdar confirmed the potential move durin
Novo Nordisk CEO Mike Doustdar forecasts oral obesity drugs may comprise half the global market by 2030 as the company advances five oral treatments. Holding over 80% of new oral prescriptions, Novo a
Novo Nordisk and UNICEF expanded their partnership to prevent childhood obesity, committing $18 million from 2026 to 2030. The initiative aims to reach over 80 million children across seven countries
Novo Nordisk announced its experimental drug CagriSema achieved 12.4% average weight loss in late-stage diabetes trials, outperforming Eli Lilly's tirzepatide at 9.1%. The combination therapy position
Novo Nordisk faces investor pressure to diversify beyond its blockbuster weight-loss drugs amid rising competition from Eli Lilly and impending semaglutide patent expiries. Analysts suggest acquisitio
Novo Nordisk has partnered with Anthropic to integrate Claude AI models into its R&D workflows for accelerated drug discovery. The collaboration aims to shorten research timelines and improve scientif
Novo Nordisk CEO Mike Doustdar unveiled "The Novo Way" cultural strategy to regain market leadership against rival Eli Lilly in the obesity drug sector. The initiative emphasizes customer obsession as
Eli Lilly announced its oral obesity drug Foundayo captured over 30% of new US patients, narrowing the gap with rival Novo Nordisk. Market analysts expect the obesity treatment sector to reach over $1
Asian equities trend lower amid rising oil prices and inflation fears, while copper reaches record highs. Corporate updates include Novo Nordisk halting heart disease trials and ADNOc exploring refini
Novo Nordisk halted two additional trials of its experimental heart drug ziltivekimab following earlier failure, hindering efforts to diversify beyond its obesity franchise. One remaining trial will c
Novo Nordisk reported that 40.4% of children aged 6 to under 12 treated with semaglutide were no longer classified as obese after 68 weeks in the STEP Young trial. Safety profiles remained consistent
Novo Nordisk launched its oral Wegovy weight-loss pill in Germany following EU approval, intensifying competition with Eli Lilly in the expanding GLP-1 market. This semaglutide-based treatment targets
Novo Nordisk confirmed China's drug regulator accepted its application for an oral version of Wegovy, joining competitors like Eli Lilly in the expanding Chinese weight-loss market. Analysts project G
Major pharmaceutical companies employ indirect marketing to promote weight-loss drugs in China amidst strict regulations. Analysts project the GLP-1 therapy market could reach $4 billion within five t
Novonesis and Novo Nordisk expect results by late 2027 from research on whether microbiome supplements can benefit users of GLP-1 weight-loss drugs.
Novo Holdings, the investment arm of Novo Nordisk, has resumed full capital allocations targeting US renewables and AI infrastructure, citing improved valuation and market stability despite ongoing ta
Hims & Hers raised its full-year revenue guidance to $3.1–$3.3 billion after reporting $753 million in quarterly revenue. The growth was driven by a partnership with Novo Nordisk to offer the FDA-appr
Britain's MHRA approved Eli Lilly's oral weight-loss pill Foundayo for diabetes and weight management, marking the first European authorization. The drug launches privately later this month, intensify
Novo Nordisk shares climbed 35% as its oral Wegovy competes strongly against Eli Lilly's Zepbound in the projected $100 billion obesity market. Investors await Q2 results to assess the durability of t
Novo Nordisk sued Eli Lilly over allegedly misleading advertising for their weight-loss drugs, claiming the rival used outdated studies to imply superiority. Eli Lilly defended its campaign, citing di
Novo Nordisk sued Eli Lilly in U.S. court, alleging false advertising claims comparing their weight-loss drugs Zepbound and Wegovy. The lawsuit underscores fierce competition in the obesity market, re
Sun Pharma received South African regulatory approval to manufacture and sell a generic version of semaglutide, challenging Novo Nordisk and Eli Lilly in the diabetes and obesity drug market.
Novo Nordisk and Eli Lilly’s GLP-1 weight-loss drugs are transforming consumer spending, boosting apparel sales while causing sharp declines in plus-size retail. Market analysts predict significant sh
Novo Nordisk launched its once-weekly basal insulin Awiqli in India to treat type 1 and 2 diabetes. The product reduces injection frequency to 52 times yearly, competing in a market projected to reach
Eli Lilly executives state their oral GLP-1 drug orforglipron may gain China approval between late 2026 and early 2027. Rival Novo Nordisk also plans to seek approval soon as competition grows in the
Cyber extortion group FulcrumSec claims to have stolen over a terabyte of data from Novo Nordisk, including drug trial information and production facility details, after demanding a $25 million ransom
Novo Nordisk plans to seek Chinese regulatory approval for its oral Wegovy pill very soon, CEO Mike Doustdar said. The company aims to compete with Eli Lilly in China's rapidly expanding GLP-1 market,
European stocks rallied over 1% as Brent crude oil prices fell following President Trump's cancellation of planned strikes on Iran. Novo Nordisk shares rose after its oral weight-loss pill received UK
Novo Nordisk confirmed a cyberattack where unauthorized copies of patient data from certain clinical trials were taken. While core operations remain unaffected, the company has launched an investigati
ChemBrief